Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

791 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix.
Campbell P, Gebrael G, Narang A, Chehade CH, Thomas VM, Galarza Fortuna G, Sayegh N, Tripathi N, Tandar C, Dal E, Li H, Swami U, Agarwal N, Maughan BL. Campbell P, et al. Among authors: narang a. Ther Adv Urol. 2024 Nov 8;16:17562872241293779. doi: 10.1177/17562872241293779. eCollection 2024 Jan-Dec. Ther Adv Urol. 2024. PMID: 39524157 Free PMC article.
Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
Gebrael G, Hage Chehade C, Sayegh N, Tripathi N, Chigarira B, Goel D, Nordblad B, McFarland TR, Narang A, Srivastava A, Tandar C, Dal E, Jo Y, Galarza Fortuna G, Mathew Thomas V, Sahu KK, Li H, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Among authors: narang a. Prostate. 2024 Jun;84(9):888-892. doi: 10.1002/pros.24696. Epub 2024 Apr 1. Prostate. 2024. PMID: 38561317
Editorial Comment.
Narang A, Agarwal N. Narang A, et al. Urol Pract. 2024 Jan;11(1):161. doi: 10.1097/UPJ.0000000000000487.01. Epub 2024 Jan 1. Urol Pract. 2024. PMID: 38117973 No abstract available.
Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor.
Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, Srivastava A, Nordblad B, Dal E, Narang A, Brundage J, Campbell P, Galarza Fortuna G, Hage Chehade C, Maughan BL, Agarwal N, Swami U. Gebrael G, et al. Among authors: narang a. Cancer. 2024 Aug 1;130(15):2621-2628. doi: 10.1002/cncr.35302. Epub 2024 Apr 2. Cancer. 2024. PMID: 38564301
Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami U. Mathew Thomas V, et al. Among authors: narang a. JAMA Netw Open. 2024 May 1;7(5):e249417. doi: 10.1001/jamanetworkopen.2024.9417. JAMA Netw Open. 2024. PMID: 38696168 Free PMC article.
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.
Gebrael G, Jo Y, Swami U, Plets M, Hage Chehade C, Narang A, Gupta S, Myint ZW, Sayegh N, Tangen CM, Hussain M, Dorff T, Lara PN Jr, Lerner SP, Thompson I, Agarwal N. Gebrael G, et al. Among authors: narang a. JAMA Netw Open. 2024 Jul 1;7(7):e2419966. doi: 10.1001/jamanetworkopen.2024.19966. JAMA Netw Open. 2024. PMID: 38980676 Free PMC article. Clinical Trial.
Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers.
Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, Agarwal N, Swami U. Hage Chehade C, et al. Among authors: narang a. JAMA Netw Open. 2024 Jul 1;7(7):e2423186. doi: 10.1001/jamanetworkopen.2024.23186. JAMA Netw Open. 2024. PMID: 39023888 Free PMC article.
Talazoparib for the treatment of prostate cancer.
Narang A, Hage Chehade C, Ozay ZI, Nordblad B, Swami U, Agarwal N. Narang A, et al. Expert Opin Pharmacother. 2024 Sep;25(13):1717-1727. doi: 10.1080/14656566.2024.2397002. Epub 2024 Aug 29. Expert Opin Pharmacother. 2024. PMID: 39210559 Review.
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations.
Narang A, Gebrael G, Jo Y, Thomas VM, Li H, Fortuna GG, Sayegh N, Tandar C, Tripathi N, Chigarira B, Srivastava A, Hage Chehade C, Nordblad B, Maughan BL, Agarwal N, Swami U. Narang A, et al. Kidney Cancer. 2024 Sep 5;8(1):135-142. doi: 10.3233/KCA-240016. eCollection 2024. Kidney Cancer. 2024. PMID: 39263256 Free PMC article.
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.
Swami U, Jo Y, Narang A, Plets M, Hage Chehade C, Gebrael G, Gupta S, Myint Z, Tangen C, Lara PN Jr, Thompson IM Jr, Hussain MHA, Dorff TB, Lerner SP, Agarwal N. Swami U, et al. Among authors: narang a. Eur Urol Oncol. 2024 Nov 8:S2588-9311(24)00241-4. doi: 10.1016/j.euo.2024.10.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39521639
791 results